Tissue Regenix (TRX) has a broad portfolio of regenerative medicine products for the biosurgery, orthopaedics, dental and cardiac markets. The company has two proprietary decellularised technology platforms for the repair of tissues and bone. 2017 was a dynamic year for the group, growth being boosted by the acquisition of CellRight Technologies. This was borne out by full-year results. Although sales were in line with forecasts, control of costs reduced the EBIT loss and generated a stronger balance sheet. Management is continuing to integrate and streamline the business, and is seeking distribution partnerships to maximise the opportunities.
If you'd like to be introduced to the team at Tissue Regenix, get in touch.Request a meeting